The Company has received notification from Richard Dennis, Chief Commercial Officer, that on 12 April and 13 April 2021 he purchased, in aggregate, 625,000 Ordinary Shares in the Company at an average price of 5.22p per share. Richard Dennis now holds 625,000 Ordinary Shares in the Company, which represents approximately 0.21% of the issued share capital of the Company.
The Annual Report and Financial Statements for the year ended 31 December 2020, together with a notice of the Annual General Meeting is available to view on the Companies website www.proteomics.com and will be posted to shareholders imminently.
Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 31 March 2021.
Proteome Sciences PLC is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company’s results for the year ended 31 December 2020 via the Investor Meet Company platform on Thursday, 8 April 2021 at 10.00am BST.
The Company is pleased to announce its audited results for the year ended 31 December 2020.
On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited (“VIM”) (the “Loan”). The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 1 May 2022 (previously 1 May 2021) (the “Loan Amendment”). All other terms of the Loan remain the same as announced on 3 July 2018, including that interest will accrue at the annual rate of 2.5 per cent. above the UK sterling base rate of Barclays Bank plc.
Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 29 March 2021.
Following the Company’s announcement on 25 January 2021 the Company has been progressing the year end audit and anticipates being able to announce the 2020 full year results on Thursday, 1 April 2021. The Directors of Proteome Sciences are pleased to announce that the Company now expects to report profit after tax materially higher than announced on 25 January. This is primarily due to higher than expected royalty receipts from Thermo Scientific for the last quarter of 2020. The annual results are still subject to finalisation of the audit and approval by the Board.
Proteome Sciences’ proprietary TMTcalibrator™ workflow for tissue-enhanced phosphoproteomics in Alzheimer’s disease CSF featured in new publication from Cognition Therapeutics, Inc. Results show that CT1812 treatment reduces levels of phosphorylation on CSF tau including at many sites only quantifiable using TMTcalibrator™. Citation: “Izzo NJ, Yuede CM, LaBarbera KM, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021;1-18. https://doi.org/10.1002/alz.
The Company today provides a trading update for the financial year ended 31 December 2020.